HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Adjusted indirect comparison of celecoxib versus rofecoxib on cardiovascular risk.

Abstract
To compare the magnitude of celecoxib versus rofecoxib on the cardiovascular risk. We performed adjusted indirect comparison of celecoxib versus rofecoxib for cardiovascular events using two data on The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial and Adenoma Prevention with Celecoxib (APC) trial. Baseline characteristics of the patients and placebos were comparable in both trials, in terms of age, sex, hypertension, diabetes mellitus, smoking, and hypercholesterolemia. The overall incidence of cardiovascular events was similar in both groups (rofecoxib 48/1,287 versus celecoxib 48/1,356, p = 0.79). The relative risks (RRs) of all myocardial infarction or sudden death from cardiac causes were increased in both rofecoxib and celecoxib groups [rofecoxib versus placebo; RR 1.35, 95% confidence interval (CI) 1.07-1.69, p = 0.03, celecoxib versus placebo; RR 1.35, 95% CI 1.14-1.51, p = 0.01]. The RRs for cardiovascular events derived from the adjusted indirect comparisons of the two coxibs did not significantly differ from unity (celecoxib versus rofecoxib; RR 0.95, 95% CI 0.76-1.19, p = 0.67). The adjusted indirect comparison analysis shows that celecoxib and rofecoxib may have similarly effect of cardiovascular events when used for 3 years.
AuthorsYoung Ho Lee, Jong Dae Ji, Gwan Gyu Song
JournalRheumatology international (Rheumatol Int) Vol. 27 Issue 5 Pg. 477-82 (Mar 2007) ISSN: 0172-8172 [Print] Germany
PMID17051359 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Cyclooxygenase Inhibitors
  • Lactones
  • Pyrazoles
  • Sulfonamides
  • Sulfones
  • rofecoxib
  • Celecoxib
Topics
  • Adenoma (prevention & control)
  • Adenomatous Polyps (prevention & control)
  • Angina, Unstable (chemically induced)
  • Celecoxib
  • Cyclooxygenase Inhibitors (adverse effects)
  • Humans
  • Lactones (adverse effects)
  • Middle Aged
  • Myocardial Infarction (chemically induced)
  • Pyrazoles (adverse effects)
  • Risk
  • Sulfonamides (adverse effects)
  • Sulfones (adverse effects)
  • Thromboembolism (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: